Experiment Overview
| Repository ID: | FR-FCM-ZYS6 | Experiment name: | GEN501 Clinical Trial / Bone Marrow | MIFlowCyt score: | 51.50% |
| Primary researcher: | Yann Abraham | PI/manager: | Greet Vanhoof | Uploaded by: | Yann Abraham |
| Experiment dates: | 2015-12-07 - 2016-01-15 | Dataset uploaded: | Nov 2018 | Last updated: | Mar 2019 |
| Keywords: | [mass cytometry] [CyTOF] [multiple myeloma] [clinical trial] [daratumumab] [darzalex] | Manuscripts: | [30536810] |
|
|
| Organizations: |
Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Turnhout, (Belgium)
|
||||
| Purpose: | The objective of this study was to identify novel changes in immune cell phenotypes that correlate with the efficacy and depth of response observed during treatment with daratumumab in patients with relapsed refractory multiple myeloma. | ||||
| Conclusion: | CyTOF® analysis of patient samples from studies of daratumumab therapy highlight the immune-modulatory mechanism of action of daratumumab. T-cell changes toward a cytolytic, granzyme B+ phenotype observed in WB and BM and increased expression of the activation markers on NK cells, such as CD69, support an adaptive response in patients that may contribute to the depth of response observed in patients treated with daratumumab | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | Each experiment includes a full panel stained WB healthy volunteer control sample, a panel minus CD38 metal (FMO) stained control WB sample and a full panel stained PBMC sample. Data acquired on CyTOF® were collected in an FCS file format and normalized using CyTOF® Software 6.5.358 for Stand-Alone Processing Workstations (Fluidigm). To ensure that every cell population was represented, the analysis included only samples in which at least 10,000 events in the lymphocyte/monocyte population had been recorded. | ||||
Experiment variables
| Sample Type | |
|---|---|
| · Sample | 104_1_Lympho mono 45 neg.fcs · 11_1_Lympho mono 45 neg.fcs · 14_1_Lympho mono 45 neg.fcs · 22_1_Lympho mono 45 neg.fcs · 24_1_Lympho mono 45 neg.fcs · 36_1_Lympho mono 45 neg.fcs · 38_1_Lympho mono 45 neg.fcs · 41_1_Lympho mono 45 neg.fcs |
